Daiichi Sankyo Expands Puerto Rico Sales Force
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Daiichi Sankyo completed lining up a Puerto Rico sales force and will now accelerate sales expansion of its core lines of products in Puerto Rico, offering the same products as those being sold in the United States by taking advantage of its U.S. commonwealth status, enabling the company to sell products approved by the U.S. FDA, Daiichi Sankyo spokesperson Maho Tanabe told PharmAsia News Jan. 13
You may also be interested in...
Daiichi Sankyo Optimistically Ramping Up For Prasugrel Launch
Daiichi Sankyo CEO Takashi Shoda acknowledged during the company's third quarter results call that the delay in U.S. FDA approval of Effient (prasugrel), a novel platelet inhibitor that the company filed jointly with Eli Lilly in December 2007, has negatively affected the company net sales forecast
Daiichi Sankyo Optimistically Ramping Up For Prasugrel Launch
Daiichi Sankyo CEO Takashi Shoda acknowledged during the company's third quarter results call that the delay in U.S. FDA approval of Effient (prasugrel), a novel platelet inhibitor that the company filed jointly with Eli Lilly in December 2007, has negatively affected the company net sales forecast
U.S. FDA Confirms Daiichi/Lilly Prasugrel Advisory Committee Review; What Will Panel Membership Entail?
As preparations get underway for the Feb. 3 advisory committee review of Lilly and Daiichi Sankyo's platelet inhibitor prasugrel, one indicator of the drug's prospects will be the individuals who are asked by U.S. FDA to serve on the expert panel